Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00633893 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
A Phase 3 study of Venous Thrombosis, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,711
- Enrollment target
- 20
- Study locations
NCT00633893 is a Phase 3 study of Venous Thrombosis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 2,711 participants, above the 824-participant average among 9 other Venous Thrombosis trials with a reported enrollment target (229% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT00633893, a Phase 3 study of Venous Thrombosis, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,711 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients who have completed their intended treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Apixaban
Study Locations (20)
California
- Beaver Medical Group - Banning
- Scripps Clinic/Scripps Health And Green Hospital - La Jolla
- Healthcare Partners Medical Group - Los Angeles
- Mission Internal Medical Group - Mission Viejo
- Desert Med Grp Inc, Dba Desert Oasis Healthcare Med Group - Palm Springs
- Indus Clinical Research Institute, Inc. - Pomona
- Kaiser Permanente Medical Center - San Francisco
- Stanford University Medical Center - Stanford
- Harbor Ucla Medical Center - Torrance
- Progressive Clinical Research - Vista
Florida
- Bay Pines Va Healthcare Systems - Bay Pines
- Research Alliance, Inc. - Clearwater
- St. Francis Sleep Allergy & Lung Institute - Clearwater
Arizona
- Cardiovascular Consultants, Ltd. - Phoenix
- Robert J. Bloomberg, Md, Pc - Tempe
Colorado
- Rocky Mountain Internal Medicine - Aurora
- New West Physicians - Golden
Alabama
- Alabama Clinical Therapeutics, Llc - Birmingham
Arkansas
- Fort Smith Lung Center - Fort Smith
Delaware
- Alfieri Cardiology - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,711 participants |
| Start Date | 2008-05 |
| Est. Completion | 2012-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00633893
The ClinicalTrials.gov registry entry for NCT00633893 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,711 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 824-participant average among 9 other Venous Thrombosis trials with a reported enrollment target (229% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Venous Thrombosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00633893 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00633893 about?
NCT00633893 is a clinical study titled "Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism". The purpose is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients who have completed their intended treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE)
What is the current status of trial NCT00633893?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,711 participants. The study started on 2008-05. Estimated completion is 2012-08.
What conditions does trial NCT00633893 study?
This clinical trial studies the following conditions: Venous Thrombosis.
What interventions are being tested in trial NCT00633893?
The interventions under investigation include: Placebo (DRUG), Apixaban (DRUG).
Who is sponsoring clinical trial NCT00633893?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00633893 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Venous Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism
COMPLETED · Phase 3
-
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
COMPLETED · Phase 3
-
Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters
COMPLETED · Phase 3
-
JETi Lower Extremity Venous Thrombosis
ACTIVE NOT RECRUITING
-
Registry of AngioJet Use in the Peripheral Vascular System
COMPLETED
-
Peripherally Inserted Central Catheter (PICC) Thrombosis: Reverse Taper Versus Non-tapered Catheters
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.